tbuckley/cabot-search huggingface dataset:
A Preoperative Program for Patients Awaiting Coronary Artery Bypass Graft (CABG) Surgery
Journal: Annals of Internal Medicine (2000)

Summaries for Patients15 August 2000A Preoperative Program for Patients Awaiting Coronary Artery Bypass Graft (CABG) SurgerySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-4-200008150-00036 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?In some countries, patients often have to wait for medical procedures such as coronary artery bypass graft (CABG) surgery. In CABG surgery, blocked blood vessels that deliver blood to the heart are replaced with artificial vessels or ones taken from elsewhere in the body. For many patients, CABG is elective, meaning that it is judged to be relatively safe for them to wait for surgery. However, patients' emotional state and ability to perform their usual activities can deteriorate while they wait. Since waits for CABG can't always be ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Effect of a Preoperative Intervention on Preoperative and Postoperative Outcomes in Low-Risk Patients Awaiting Elective Coronary Artery Bypass Graft Surgery. A Randomized, Controlled Trial.” It is in the 15 August 2000 issue of Annals of Internal Medicine (volume 133, pages 253-262). The authors are H.M. Arthur, C. Daniels, R. McKelvie, J. Hirsh, and B. Rush.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffect of a Preoperative Intervention on Preoperative and Postoperative Outcomes in Low-Risk Patients Awaiting Elective Coronary Artery Bypass Graft Surgery Heather M. Arthur , Charlotte Daniels , Robert McKelvie , Jack Hirsh , and Bonnie Rush Metrics 15 August 2000Volume 133, Issue 4Page: 253KeywordsAnxietyBlood vesselsCoronary arteriesExerciseIntensive care unitsMedical servicesPatientsQuality of lifeSurgeryThoracic surgery ePublished: 15 August 2000 Issue Published: 15 August 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
TCT-625 Long term clinical data of the BIOSOLVE-I study with the paclitaxel-eluting absorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis
Authors: Michael Haude, Raimund Erbel, Paul Erne, Stefan Verheye, Paul Vermeersch, Hubertus Degen, Dirk Boese, Ron Waksman, Neil Weissman, Francesco Prati, Jacques Koolen
Journal: Journal of the American College of Cardiology (2014)
BTK Inhibitor May Treat Drug-Resistant CLL, SLL
Journal: Cancer Discovery (2021)

Abstract A reversible BTK inhibitor, pirtobrutinib, could be effective for patients with B-cell malignancies whose disease has worsened on other targeted therapies or who cannot tolerate the toxicity of irreversible BTK inhibitors. In a phase I/II trial, patients previously treated with other BTK inhibitors had an overall response rate of 62% to pirtobrutinib.
JAMA 75 YEARS AGO
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 64: HDL Glycosylation is Associated with HDL’s Anti-Inflammatory Function and is Responsive to Dietary Intervention
Authors: Angela M Zivkovic, Christopher Rhodes, Romina Sacchi, Elizabeth Beals, Lisa Sawrey-Kubicek, Chenghao Zhu, John K Muchena, Guillaume Luxardi, Emanual Maverakis, Carlito B Lebrilla
Journal: Circulation Research (2017)

Although HDL cholesterol (HDL-C) levels are protective against cardiovascular disease (CVD) risk, raising HDL-C pharmaceutically has not led to improvements in cardiovascular outcomes. It is becoming clear that HDL composition and function are more important than HDL concentrations in determining risk. This study set out to determine whether glycosylation differences in HDL-associated glycoproteins affect HDL’s anti-inflammatory function. HDL were purified from healthy subjects (n=10), who consumed in randomized order a fast food (FF) diet and a Mediterranean (Med) diet for 4 days, with a 4-day washout between arms. All foods were provided in this isocaloric cross-over intervention trial, which was approved by the UC Davis IRB. Concentrations of HDL-bound serum amyloid A (SAA), apolipoprotein A-I (ApoA-I), apolipoprotein C-III (ApoC-III), α-1-antitrypsin (A1AT), and α-2-HS-glycoprotein (A2HSG); and the site-specific glycosylation of ApoC-III, A1AT, and A2HSG were measured. Secretion of TNF-α in stimulated monocytes was measured to assess HDL anti-inflammatory function. HDL glycosylation was altered by the dietary interventions and correlated with changes in the amount of TNF-α secreted by stimulated monocytes. HDL glycosylation profiles were different in response to the FF diet vs. the Med diet. HDL with a diminished capacity to suppress TNF-α secretion were enriched in ApoC-III and desialylated A2HSG, depleted in A1AT, and had lower levels of sialylation across glycoproteins. Our results demonstrate that HDL glycoprotein composition, including site-specific glycosylation, is responsive to dietary intervention and correlates with HDL’s ability to modulate TNF-α response in stimulated monocytes. These data suggest that the measurement of HDL glycosylation profiles may be useful in stratifying CVD risk and detecting individuals with impaired HDL anti-inflammatory function.
Evaluation of iron status
Authors: C. A. Finch
Journal: JAMA (1984)

It may be worthwhile to put in perspective the changes that occur with iron depletion and how they may be measured.<sup>1</sup>Let us suppose that sequential measurements are made in a person who, because of continued bleeding from internal hemorrhoids, has a negative iron balance. The first change will be a reduction in iron stores, which can most conveniently be measured by a ferritin determination. A decrease of 1 μg/L in plasma ferritin will correspond with a decrease in body iron stores of about 120 μg/kg. As stores become depleted, the total iron binding capacity of the plasma will rise and iron absorption will increase. The current article by Crosby and O'Neil-Cutting<sup>2</sup>illustrates the use of the plasma iron tolerance test to demonstrate the latter. Such changes occur without an effect on the plasma iron concentration or transferrin saturation (plasma iron-total iron binding capacity). It is only when
Response to Letter to Editor
Authors: Timothy J Kaufmann, Marion Smits, Jerrold Boxerman, Raymond Huang, Daniel P Barboriak, Michael Weller, Caroline Chung, Christina Tsien, Paul D Brown, Lalitha Shankar, Evanthia Galanis, Elizabeth Gerstner, Martin J van den Bent, Terry C Burns, Ian F Parney, Gavin Dunn, Priscilla K Brastianos, Nancy U Lin, Patrick Y Wen, Benjamin M Ellingson
Journal: Neuro-Oncology (2020)
A Clinical Update on Gestational Diabetes Mellitus
Authors: Arianne Sweeting, Jencia Wong, Helen R Murphy, Glynis P Ross
Journal: Endocrine Reviews (2022)

Gestational diabetes mellitus (GDM) traditionally refers to abnormal glucose tolerance with onset or first recognition during pregnancy. GDM has long been associated with obstetric and neonatal complications primarily relating to higher infant birthweight and is increasingly recognized as a risk factor for future maternal and offspring cardiometabolic disease. The prevalence of GDM continues to rise internationally due to epidemiological factors including the increase in background rates of obesity in women of reproductive age and rising maternal age and the implementation of the revised International Association of the Diabetes and Pregnancy Study Groups' criteria and diagnostic procedures for GDM. The current lack of international consensus for the diagnosis of GDM reflects its complex historical evolution and pragmatic antenatal resource considerations given GDM is now 1 of the most common complications of pregnancy. Regardless, the contemporary clinical approach to GDM should be informed not only by its short-term complications but also by its longer term prognosis. Recent data demonstrate the effect of early in utero exposure to maternal hyperglycemia, with evidence for fetal overgrowth present prior to the traditional diagnosis of GDM from 24 weeks' gestation, as well as the durable adverse impact of maternal hyperglycemia on child and adolescent metabolism. The major contribution of GDM to the global epidemic of intergenerational cardiometabolic disease highlights the importance of identifying GDM as an early risk factor for type 2 diabetes and cardiovascular disease, broadening the prevailing clinical approach to address longer term maternal and offspring complications following a diagnosis of GDM.
COVID-19: we will not be returning to the old normal
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2020)

Recently there has been a gradual shift in the COVID-19 discourse based on an acknowledgement that clearer communication is needed to manage public expectations. Although not directly factored into this shift of tone, the so-called fatalism effect can teach us something. This concept essentially warns that if a problem is characterised as nearly insurmountable then many people will just give up. These people surmise that the cost of the intervention is not worth it, given they perceive that the cost yields little benefit.
Abstract 429: Assessment of Functional Mitochondrial Parameters in Single Cardiomyocytes Reveals Critical Events Not Identified in Cell Populations
Authors: Giovanni Fajardo, Kristina Kooiker, Mingming Zhao, Michael Coronado, Gwanghyun Jung, Dong-Qing Hu, Sushma Reddy, Daniel Bernstein
Journal: Circulation Research (2017)

In cardiomyocytes (CMs), mitochondria play a dual role, maintaining the high energy supply required for rhythmic contraction, but also regulating critical cell death signaling. Impaired mitochondrial function can affect cellular homeostasis and contribute to sub-lethal injury; if mitochondrial impairment is more severe or persistent, pro-death pathways are activated. It is becoming increasingly clear, however, that within a population of cells there is considerable heterogeneity in mitochondrial function between individual CMs; and within a single cell there is also heterogeneity between individual mitochondria/mitochondrial regions. We have developed a high-throughput fluorescence imaging platform to quantitate single CM mitochondrial function in large numbers of cells, yielding information missed using standard assays that evaluate cell populations. When CMs are exposed to H 2 O 2 , they exhibit a dramatic hyperpolarization prior to the loss of mitochondrial membrane potential at the onset of cell contraction and death. There is marked heterogeneity in the timing of this response, with three distinct populations identified using Gaussian mixture models, and the duration of hyperpolarization longer for CMs that hypercontract earlier after H 2 O 2 exposure. This hyperpolarization is accompanied by a simultaneous increase in [Ca 2+ ] i and is preceded by an increase in ROS. Standard methods, which average populations of cells, miss these responses. Blockade of MPT opening with cyclosporine A delays hypercontracture and cell death but does not prevent hyperpolarization. Finally, we have used our platform to track individual mitochondria/mitochondrial regions within a single live CM, identifying mitochondrial heterogeneity within a single cell, which is increased after exposure to H 2 O 2 , isoproterenol or in CMs from mice after ischemia-reperfusion injury. By tracking individual CMs and individual mitochondria within a single CM, we have opened a window to the complex heterogeneities in mitochondrial stress response.
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Authors: Andrew B. Nixon, Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Alan P. Venook, Luis Baez-Diaz, Heinz-Josef Lenz, Bert H. O'Neil, Federico Innocenti, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Kouros Owzar, Herbert I. Hurwitz
Journal: Clinical Cancer Research (2021)

CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy group and the bevacizumab-chemotherapy group, biomarkers could identify patients deriving more benefit from either biologic agent.In this exploratory analysis, the Angiome, a panel of 24 soluble protein biomarkers were measured in baseline plasma samples in CALGB 80405. Prognostic biomarkers were determined using univariate Cox proportional hazards models. Predictive biomarkers were identified using multivariable Cox regression models including interaction between biomarker level and treatment.In the total population, high plasma levels of Ang-2, CD73, HGF, ICAM-1, IL6, OPN, TIMP-1, TSP-2, VCAM-1, and VEGF-R3 were identified as prognostic of worse progression-free survival (PFS) and overall survival (OS). PlGF was identified as predictive of lack of PFS benefit from bevacizumab [bevacizumab HR, 1.51; 95% confidence interval (CI), 1.10-2.06; cetuximab HR, 0.94; 95% CI, 0.71-1.25; Pinteraction = 0.0298] in the combined FOLFIRI/FOLFOX regimens. High levels of VEGF-D were predictive of lack of PFS benefit from bevacizumab in patients receiving FOLFOX regimen only (FOLFOX/bevacizumab HR, 1.70; 95% CI, 1.19-2.42; FOLFOX/cetuximab HR, 0.92; 95% CI, 0.68-1.24; Pinteraction = 0.0097).In this exploratory, hypothesis-generating analysis, the Angiome identified multiple prognostic biomarkers and two potential predictive biomarkers for patients with mCRC enrolled in CALGB 80405. PlGF and VEGF-D predicted lack of benefit from bevacizumab in a chemo-dependent manner. See related commentaries by Mishkin and Kohn, p. 2722 and George and Bertagnolli, p. 2725.
Tumor regression grade and overall survival following gastrectomy with neoadjuvant therapy for gastric cancer.
Authors: Michelle A Savoldy, Andrew J Sinnamon, Rutika Mehta, Luis Pena, Sean P. Dineen, Gregory Y Lauwers, Jose Mario Pimiento
Journal: Journal of Clinical Oncology (2022)

355 Background: Perioperative chemotherapy is the standard of care for locoregional gastric cancers in western populations. However, the impact of response to therapy as a biomarker of cancer survival has not been fully defined. This study focuses on the pathological response to neoadjuvant chemotherapy, as measured by tumor regression grade (TRG), for gastric cancer and its impact on patient outcomes, primarily overall survival. Methods: Patients undergoing gastrectomy for nonmetastatic invasive gastric adenocarcinoma following perioperative chemotherapy (clinical T2+/N+cM0) were identified from an institutional database (2000-2021). Demographics, clinical staging including histologic grade, surgical factors and survival outcomes were included. The association between TRG and overall survival from time of surgery was assessed. OS was estimated using the Kaplan Meier method with adjustment for covariates using Cox regression. Results: One hundred seventeen patients were identified. Median age was 65 years (IQR 57–73). The majority of the patients were male (n = 64, 55%). Seventy-six patients underwent total gastrectomy, 22 subtotal gastrectomy, and 19 distal gastrectomy. Six patients (5.1%) had a TRG of 0, 18 patients (15.4%) had a TRG of 1, 25 patients (21.4%) had a TRG of 2, and 68 patients (58.1%) had a TRG of 3. Median survival overall was 40.9 months (95% CI 28.7–66.4). TRG status was not significantly different between chemotherapy regimens (doublet vs triplet, p = 0.96). Median survival was longest in the TRG 0 group (86.9 months), followed sequentially by TRG 1 (74.5 months), TRG 2 (51.5 months), and lastly, TRG 3 group with 27.0 months. Increased tumor regression (lower TRG) was significantly associated with prolonged survival (p &lt; 0.01 by log-rank for trend). After adjustment for clinical patient factors and tumor factors, TRG remained significantly associated with overall survival (Table; TRG hazard ratio 1.62, p = 0.007). In addition to TRG status, clinical T4 tumors and diffuse histology were associated with poor survival (cT4 hazard ratio 2.09, p = 0.039, diffuse histology hazard ratio 1.82 (p = 0.071). Conclusions: In patients receiving perioperative chemotherapy for treatment of gastric cancer, response to therapy as defined by TRG is independently prognostic of survival.[Table: see text]
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System
Authors: Jonathan L. Halperin, Glenn N. Levine, Sana M. Al-Khatib, Kim K. Birtcher, Biykem Bozkurt, Ralph G. Brindis, Joaquin E. Cigarroa, Lesley H. Curtis, Lee A. Fleisher, Federico Gentile, Samuel Gidding, Mark A. Hlatky, John Ikonomidis, José Joglar, Susan J. Pressler, Duminda N. Wijeysundera
Journal: Journal of the American College of Cardiology (2015)
Results of Sympathectomy in Raynaud's Phenomenon
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Two-year follow-up after catheter-based beta-radiation therapy Ken Kozyma, Alexander J. Wardeh, Willem J. van der Giessen, Arie H. M. Knook, Veronique L. M. A. Coen, Jurgen M. R. Ligthart, David P. Foley, Pim J. de Feyter, Peter C. Levendag, Patrick W. Serruys. Thoraxcenter, Rotterdam, The Netherlands, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Abstract 85: The AAA-ATPase p97 is a Critical Regulator of Cardiac Homeostasis
Authors: Matthew J Brody, Michelle A Sargent, Jeffery D Molkentin
Journal: Circulation Research (2017)

p97 is a AAA-ATPase that plays critical roles in a myriad of cellular protein quality control processes, including the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway that targets misfolded proteins in the ER for degradation in the cytosol by the ubiquitin proteasome system. Mutations in p97 cause a multisystem degenerative proteinopathy disorder called inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD) that includes pathologies of the nervous system, skeletal muscle, bone, and heart. Previous studies in the laboratory into the mechanisms whereby thrombospondin 4 has its cardioprotective effects and enhanced ERAD activity identified p97 as a direct interacting partner. This observation suggested that p97 itself could be an important cardioprotective effector by benefiting protein quality control in the heart. To address this hypothesis here we generated cardiac-specific transgenic mice overexpressing wildtype p97 or a p97 K524A mutant with deficient ATPase activity, the latter of which functioned as a dominant negative. Mice overexpressing wildtype p97 exhibit normal cardiac structure and function while mutant p97 overexpressing mice develop cardiomyopathy, upregulate several ERAD complex components, and have elevated levels of ubiquitinated proteins. Proteomics and immunoprecipitation assays identified overwhelming interactions between endogenous p97 and a number of interesting protein complexes that suggest unique functions for this protein in regulating protein quality control in the heart. The results and novel regulatory relationships will be presented, which suggests entirely unique pathways whereby p97 functions in the heart.
Progress and objectives in cancer control
Authors: L. Breslow
Journal: JAMA (1988)

This article reviews progress in cancer control and objectives for achieving further control. In particular, rather than relying on a single composite statistic such as the age-adjusted mortality rate, this review stresses trends in cancer mortality in the United States using a cohort analysis. That method reveals a decline in cancer mortality beginning with young children in the 1950s and proceeding up the age scale in subsequent decades to those persons who were approximately 50 years of age in the mid-1980s. From age 55 years upward, the continuing increase in cancer mortality is due to epidemic lung cancer. The principal cause of that disease and what must be done to control it are well understood. The objectives for cancer control by the year 2000 set by the National Cancer Institute and the feasibility of reducing cancer mortality by as much as 25% to 50% are also considered. Increased cancer prevention research is needed. (<i>JAMA</i>1988;259:1690-1694)